SCHEMBL2484735

SCHEMBL2484735

CCCNC(CO)CCC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.54
CNR1 P21554 1/20 0.54
ADRA1A P35348 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
KDM4E B2RXH2 1/20 0.54
ABCC3 O15438 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
TSHR P16473 1/20 0.40
SIGMAR1 Q99720 1/20 0.33
TRPV3 Q8NET8 3/20 0.33
TAS1R3 Q7RTX0 1/20 0.31
TAS1R1 Q7RTX1 1/20 0.31
ALDH1A1 P00352 1/20 0.31
TLR8 Q9NR97 2/20 0.30
TLR7 Q9NYK1 1/20 0.30
HDAC7 Q8WUI4 1/20 0.30
HDAC8 Q9BY41 1/20 0.30
HDAC6 Q9UBN7 1/20 0.30
HDAC9 Q9UKV0 1/20 0.30
HDAC5 Q9UQL6 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2489804 1.00 LMNA (0.54) LMNACNR1ADRA1ATDP1KDM4E
SCHEMBL2484741 1.00 LMNA (0.54) LMNACNR1ADRA1ATDP1KDM4E
SCHEMBL598289 0.88 LMNA (0.52) LMNACNR1ADRA1ATDP1KDM4E
SCHEMBL12956362 0.87
SCHEMBL4776978 0.86 LMNA (0.50) LMNACNR1ADRA1ATDP1KDM4E
SCHEMBL11441647 0.84 LMNA (0.48) LMNACNR1ADRA1ATDP1KDM4E
SCHEMBL29067829 0.84 LMNA (0.54) LMNACNR1ADRA1ATDP1KDM4E
SCHEMBL18727407 0.84 LMNA (0.38) LMNACNR1ADRA1ATDP1KDM4E
SCHEMBL21029957 0.82
SCHEMBL4781049 0.82

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8178686-B2 Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate FUJIMOTO CO., LTD. (JP) 2012-05-15 US claimed
EP-1905760-B1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE IN THE PROCESS AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE FUJIMOTO CO LTD (JP) 2011-10-26 EP claimed
US-20100324300-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE AND PROCESS FOR PREPARING INTERMEDIATE YONEDA FUMIO 2010-12-23 US claimed
US-7807840-B2 Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate FUJIMOTO CO., LTD. (JP) 2010-10-05 US claimed
US-20090124813-A1 Process for Preparing Optically Active Aminopentane Derivative, Intermediate and Process for Preparing Intermediate FUJIMOTO CO., LTD. (JP) 2009-05-14 US claimed
EP-1905760-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE IN THE PROCESS AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE Fujimoto Co., Ltd. (JP) 2008-04-02 EP claimed
US-8178686-B2 Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate FUJIMOTO CO., LTD. (JP) 2012-05-15 US disclosed
US-8178686-B2 Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate FUJIMOTO CO., LTD. (JP) 2012-05-15 US disclosed
US-8178686-B2 Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate FUJIMOTO CO., LTD. (JP) 2012-05-15 US disclosed
EP-1905760-B1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE IN THE PROCESS AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE FUJIMOTO CO LTD (JP) 2011-10-26 EP disclosed
US-20100324300-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE AND PROCESS FOR PREPARING INTERMEDIATE YONEDA FUMIO 2010-12-23 US disclosed
US-20100324300-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE AND PROCESS FOR PREPARING INTERMEDIATE YONEDA FUMIO 2010-12-23 US disclosed
US-20100324300-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE AND PROCESS FOR PREPARING INTERMEDIATE YONEDA FUMIO 2010-12-23 US disclosed
US-7807840-B2 Process for preparing optically active aminopentane derivative, intermediate and process for preparing intermediate FUJIMOTO CO., LTD. (JP) 2010-10-05 US disclosed
US-20090124813-A1 Process for Preparing Optically Active Aminopentane Derivative, Intermediate and Process for Preparing Intermediate FUJIMOTO CO., LTD. (JP) 2009-05-14 US disclosed
US-20090124813-A1 Process for Preparing Optically Active Aminopentane Derivative, Intermediate and Process for Preparing Intermediate FUJIMOTO CO., LTD. (JP) 2009-05-14 US disclosed
US-20090124813-A1 Process for Preparing Optically Active Aminopentane Derivative, Intermediate and Process for Preparing Intermediate FUJIMOTO CO., LTD. (JP) 2009-05-14 US disclosed
EP-1905760-A1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE IN THE PROCESS AND PROCESS FOR PRODUCTION OF THE INTERMEDIATE Fujimoto Co., Ltd. (JP) 2008-04-02 EP disclosed
WO-2008000680-A1 FLUOROUS TELOMERIC COMPOUNDS AND POLYMERS CONTAINING SAME CLARIANT INTERNATIONAL LTD (CH) 2008-01-03 WO disclosed
WO-2008000681-A1 FLUOROUS TELOMERIC COMPOUNDS AND POLYMERS CONTAINING SAME CLARIANT INTERNATIONAL LTD (CH) 2008-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124813-A1 Process for Preparing Optically Active Aminopentane Derivative, Intermediate and Process for Preparing Intermediate API5, CASP5, BAD LMNA 618/4885CNR1 1907/4885ADRA1A 145/4885
US-20100324300-A1 PROCESS FOR PREPARING OPTICALLY ACTIVE AMINOPENTANE DERIVATIVE, INTERMEDIATE AND PROCESS FOR PREPARING INTERMEDIATE API5, CASP5, BAD LMNA 618/4885CNR1 1907/4885ADRA1A 145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.